Becker Ventures

At CGC Genomics (CGC) we are deeply committed to advancing the field of cancer care through complex, precision genomics analysis and report interpretation. We distill complex genomic data into concise, actionable insights for healthcare providers, reducing interpretation times and facilitating timely, personalized treatment recommendations for 10 million patients with metastatic cancer.​ Our years of experience interpreting and supporting thousands of the most complicated cancer genomics cases around the world enables CGC to offer healthcare providers timely, expert cancer genomics analysis and consultation support, delivering world-class expertise wherever and whenever needed.

Velicept Therapeutics, Inc. is a clinical development company based in Malvern, Pennsylvania, established in 2015. The company is dedicated to advancing innovative therapies for conditions such as overactive bladder (OAB) and irritable bowel syndrome (IBS), focusing on unmet medical needs. Its lead program features Solabegron, a novel and selective compound that relaxes bladder smooth muscle by stimulating beta 3-adrenoceptors. This therapeutic approach aims to enhance the quality of life for patients suffering from OAB and IBS. Velicept Therapeutics is committed to developing best-in-class treatment options to transform patient care in these areas.

AltheRx Pharmaceuticals is a privately held clinical development company established in 2010, dedicated to advancing innovative compounds in significant unmet medical markets. The company specializes in the clinical development and commercialization of its lead product, Solabegron, a novel adrenoceptor agonist aimed at treating overactive bladder (OAB) and irritable bowel syndrome (IBS). These conditions impact the quality of life for over 90 million Americans, a figure expected to rise with an aging population. Solabegron was initially discovered and developed by GlaxoSmithKline before being acquired by AltheRx in 2011. The company's leadership team possesses extensive experience in the pharmaceutical and biotechnology sectors, positioning AltheRx to optimize its development efforts through strategic partnerships.